FDA Brief

Warning letters Drugs

FDA warning letter to

Tuyo Health, Inc. dba Tuyo Health

MediumIssued Sep 9, 2025Posted Sep 16, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Tuyo Health over misleading claims for compounded semaglutide and tirzepatide sold online.

What happened

In August 2025, FDA reviewed Tuyo Health’s website at https://www.tuyohealth.com and found it offering compounded semaglutide and tirzepatide. FDA said the site claimed these products have the “same active” ingredient as FDA-approved brand-name drugs such as Wegovy, Ozempic, Zepbound, and Mounjaro. FDA said those claims are false or misleading because compounded drugs are not FDA-approved.

What FDA found

  1. The website claimed compounded semaglutide has the same active ingredient as Wegovy and Ozempic, which FDA says is false or misleading because compounded drugs are not FDA-approved.

    FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  2. The website claimed compounded tirzepatide has the same active ingredient as Zepbound and Mounjaro, which FDA says is false or misleading because compounded drugs are not FDA-approved.

    FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  3. The website’s advertising or promotion of compounded drugs was false or misleading.

    FDCA section 502(bb) [21 U.S.C. § 352(bb)]
  4. Tuyo Health introduced or delivered misbranded drugs into interstate commerce.

    FDCA section 301(a) [21 U.S.C. § 331(a)]
  5. Receiving misbranded drugs in interstate commerce and delivering or offering to deliver them is also prohibited.

    FDCA section 301(c) [21 U.S.C. § 331(c)]

What FDA wants

FDA tells Tuyo Health to take immediate action, including stopping the misleading claims, and to send a written response to CDER’s Office of Compounding Quality and Compliance within 15 working days describing corrective steps and how it will prevent recurrence.

Who should pay attention

  • telehealth companies selling compounded GLP-1 drugs
  • compounding pharmacies and their telehealth partners
  • marketers and websites promoting compounded drug products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low